Claudia Riedl
Vermogen: 1 313 $ op 31-08-2026
Vermogen: 1 313 $ op 31-08-2026
Dr. Claudia Riedl is an Independent Non-Executive Director at Vivoryon Therapeutics NV.
She is on the Board of Directors at Vivoryon Therapeutics NV.
Dr. Riedl was previously employed as a Head-Corporate Communications & Investor Relations by MorphoSys AG.
She received her doctorate degree from Technische Universität München.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-06-2025 | 1.000 ( 0% ) | 1 313 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Directeur/Bestuurslid | 01-01-2022 |
| Bedrijven | Functie | Einde |
|---|---|---|
| MORPHOSYS AG | Public Communications Contact | 01-01-2016 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
MorphoSys AG
MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Technische Universität München
Technische Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivoryon Therapeutics NV
Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau